Metabolite profiles of diabetes incidence and intervention response in the diabetes prevention program

Diabetes

Volumn 65, Issue 5, 2016, Pages 1424-1433

  Walford, Geoffrey A ^a,b   Ma, Yong ^c   Clish, Clary ^d   Florez, Jose C ^a,b   Wang, Thomas J ^e   Gerszten, Robert E ^a,b,d  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c GEORGE WASHINGTON UNIVERSITY   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^e VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC AMINO ACID; BETAINE; BRANCHED CHAIN AMINO ACID; GLUTAMIC ACID; GLUTAMINE; METFORMIN; METHIONINE SULFOXIDE; PLACEBO; PROPIONYLCARNITINE; SERINE; ANTIDIABETIC AGENT; BIOLOGICAL MARKER;

ADULT; ARTICLE; CARDIOMETABOLIC RISK; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; HIGH RISK POPULATION; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; BLOOD; CASE CONTROL STUDY; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DIET THERAPY; DRUG EFFECTS; EXERCISE; FOLLOW UP; LOW CALORY DIET; METABOLISM; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OBESITY; OVERWEIGHT; PATHOPHYSIOLOGY; RISK; UNITED STATES; UPREGULATION;

ADULT; BETAINE; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DIET, REDUCING; EXERCISE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; MALE; METFORMIN; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK; UNITED STATES; UP-REGULATION;

EID: 84962148165     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-1063     Document Type: Article

References (28)

1. Knowler WC, Barrett-Connor E, Fowler SE, et al.; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403
2. Wang TJ, Larson MG, Vasan RS, et al. Metabolite profiles and the risk of developing diabetes. Nat Med 2011;17:448-453
3. Stancáková A, Civelek M, Saleem NK, et al. Hyperglycemia and a common variant of GCKR are associated with the levels of eight amino acids in 9, 369 Finnish men. Diabetes 2012;61:1895-1902
4. Cheng S, Rhee EP, Larson MG, et al. Metabolite profiling identifies pathways associated with metabolic risk in humans. Circulation 2012;125:2222-2231
5. Palmer ND, Stevens RD, Antinozzi PA, et al. Metabolomic profile associated with insulin resistance and conversion to diabetes in the Insulin Resistance Atherosclerosis Study. J Clin Endocrinol Metab 2015;100:E463-E468
6. DPP. The Diabetes Prevention Program. Design and methods for a clinical trial in the prevention of type 2 diabetes. Diabetes Care 1999;22:623-634
7. Lewis GD, Wei R, Liu E, et al. Metabolite profiling of blood from individuals undergoing planned myocardial infarction reveals early markers of myocardial injury. J Clin Invest 2008;118:3503-3512
8. Rhee EP, Cheng S, Larson MG, et al. Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans. J Clin Invest 2011;121:1402-1411
9. Roberts LD, Souza AL, Gerszten RE, Clish CB. Targeted metabolomics. Curr Protoc Mol Biol 2012; Chapter 30:Unit 30.2. 1-24
10. The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 2000;23:1619-1629
11. American Diabetes Association. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197
12. Samuelsen SO. A psudolikelihood approach to analysis of nested casecontrol studies. Biometrika 1997;84:379-394
13. Støer NC, Samuelsen SO. Comparison of estimators in nested case-control studies with multiple outcomes. Lifetime Data Anal 2012;18:261-283
14. Ejaz A, Martinez-Guino L, Goldfine AB, et al. Dietary betaine supplementation increases Fgf21 levels to improve glucose homeostasis and reduce hepatic lipid accumulation in mice. Diabetes 2016;65:902-912
15. Magkos F, Bradley D, Schweitzer GG, et al. Effect of Roux-en-Y gastric bypass and laparoscopic adjustable gastric banding on branched-chain amino acid metabolism. Diabetes 2013;62:2757-2761
16. Walford GA, Davis J, Warner AS, et al. Branched chain and aromatic amino acids change acutely following two medical therapies for type 2 diabetes mellitus. Metabolism 2013;62:1772-1778
17. Konstantinova SV, Tell GS, Vollset SE, Nygård O, Bleie Ø, Ueland PM. Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. J Nutr 2008;138:914-920
18. Xie W, Wood AR, Lyssenko V, et al.; MAGIC Investigators; DIAGRAM Consortium; GENESIS Consortium; RISC Consortium. Genetic variants associated with glycine metabolism and their role in insulin sensitivity and type 2 diabetes. Diabetes 2013;62:2141-2150
19. Rhee EP, Ho JE, Chen MH, et al. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab 2013;18:130-143
20. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 2013;368:1575-1584
21. Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 2014;64:1908-1914
22. McCarty MF, DiNicolantonio JJ. Trimethylamine-N-oxide and heart failure. J Am Coll Cardiol 2015;66:94-96
23. McEntyre CJ, Lever M, Chambers ST, et al. Variation of betaine, N, N-dimethylglycine, choline, glycerophosphorylcholine, taurine and trimethylamine-N-oxide in the plasma and urine of overweight people with type 2 diabetes over a two-year period. Ann Clin Biochem 2015;52:352-360
24. Mueller DM, Allenspach M, Othman A, et al. Plasma levels of trimethylamine-N-oxide are confounded by impaired kidney function and poor metabolic control. Atherosclerosis 2015;243:638-644
25. Rhee EP, Souza A, Farrell L, et al. Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 2010;21:1041-1051
26. Gerszten RE, Wang TJ. The search for new cardiovascular biomarkers. Nature 2008;451:949-952
27. Rhee EP, Gerszten RE. Metabolomics and cardiovascular biomarker discovery. Clin Chem 2012;58:139-147
28. Walford GA, Ma Y, Christophi CA, et al.; Diabetes Prevention Program Research Group. Circulating natriuretic peptide concentrations reflect changes in insulin sensitivity over time in the Diabetes Prevention Program. Diabetologia 2014;57:935-939